Directed by Nawapol Thamrongrattanarit, the ad reveals how Thai credit card firm Central The 1 can make bad spending habits ...

Image Resources NL (ASX:IMA) (FRA:I5R) is pleased to advise it has successfully completed three planned shipments of heavy mineral concentrat ...

PulseSight Technologies recently announced the successful dosing of the first patient in the phase I clinical trial PST-611-CT1, investigating the safety and tolerability of PST-611 for the treatment ...

Every year, members of the carrier maintenance community come together for an annual meeting to connect with their fellow ...

The first-in-human single ascending dose study is designed to evaluate the tolerability and safety of the therapy.

PulseSight Therapeutics has announced that the first patient has been dosed in its phase 1 clinical trial evaluating PST-611, ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to announce that the first ...

View the latest Constellation Technologies Ltd. (CT1) stock price, news, historical charts, analyst ratings and financial information from WSJ.

The latest Constellation Technologies Limited [CT1] news, articles, data and analysis from The Australian Financial Review ...

The MUHC Research Ethics Board (REB) is the evaluating body for ethical and scientific review at this institution. The MUHC REB reviews all research involving humans under its auspice, to help ensure ...

Conclusions: In early-stage FOM SCC patients, SMG involvement is rare, the most common metastatic site in level 1b is the superior group, and SMG preservation does not decrease the LRC or DSS rates.

Nature Medicine today published a study showing that Perspectum's iron corrected T1, or cT1, predicts liver-related and cardiac outcomes, including morbidity. Liver disease is a modifiable cardiac ...